Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 36, 2014, Pages 13046-13051

  Cooley, Christina B ^a   Ryno, Lisa M ^a   Plate, Lars ^a   Morgan, Gareth J ^a   Hulleman, John D ^a,b   Kelly, Jeffery W ^a   Wiseman, R Luke ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Amyloid; ER proteostasis

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; AMYLOID; DNA BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; LUCIFERASE; PROTEIN AGGREGATE; REGULATORY FACTOR X TRANSCRIPTION FACTORS; THAPSIGARGIN; TRANSCRIPTION FACTOR;

CHEMISTRY; DRUG EFFECTS; EXTRACELLULAR SPACE; HEK293 CELL LINE; HUMAN; METABOLISM; PHYSIOLOGICAL STRESS; PROTEIN DEGRADATION; PROTEIN STABILITY; REPORTER GENE; SECRETION (PROCESS); UNFOLDED PROTEIN RESPONSE;

ACTIVATING TRANSCRIPTION FACTOR 6; AMYLOID; DNA-BINDING PROTEINS; EXTRACELLULAR SPACE; GENES, REPORTER; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LUCIFERASES; PROTEIN AGGREGATES; PROTEIN STABILITY; PROTEOLYSIS; STRESS, PHYSIOLOGICAL; THAPSIGARGIN; TRANSCRIPTION FACTORS; UNFOLDED PROTEIN RESPONSE;

EID: 84906993311     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1406050111     Document Type: Article

References (44)

1. Cohen AD, Comenzo RL (2010) Systemic light-chain amyloidosis: Advances in diagnosis, prognosis, and therapy. Hematology (Am Soc Hematol Educ Program) 2010:287-294.
2. Buxbaum JN, Linke RP (2012) A molecular history of the amyloidoses. J Mol Biol 421(2-3):142 - 159.
3. Jones NF, Hilton PJ, Tighe JR, Hobbs JR (1972) Treatment of "primary" renal amyloidosis with melphalan. Lancet 2(7778):616-619.
4. Jaccard A, et al.; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357(11):1083-1093.
5. Kastritis E, et al. (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28(6):1031-1037.
6. Venner CP, et al. (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387-4390.
7. Reece DE, et al. (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study. Blood 118(4):865- 873.
8. Comenzo RL, Gertz MA (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99(12):4276-4282.
9. Palladini G, et al. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103(8):2936-2938.
10. Merlini G, Seldin DC, Gertz MA (2011) Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 29(14):1924-1933.
11. Solomon A, Weiss DT, Pepys MB (1992) Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 140(3):629-637.
12. Bodi K, et al. (2009) AL-Base: A visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid 16(1):1-8.
13. Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE (2007) An adaptable standard for protein export from the endoplasmic reticulum. Cell 131(4):809-821.
14. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319(5865):916-919.
15. Smith MH, Ploegh HL, Weissman JS (2011) Road to ruin: Targeting proteins for degradation in the endoplasmic reticulum. Science 334(6059):1086-1090.
16. Lindquist SL, Kelly JW (2011) Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: Progress and prognosis. Cold Spring Harb Perspect Biol 3(12):a004507.
17. Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475(7356):324-332.
18. Sekijima Y, et al. (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121(1):73-85.
19. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78:959-991.
20. Cenci S, Sitia R (2007) Managing and exploiting stress in the antibody factory. FEBS Lett 581(19):3652-3657.
21. Ma Y, Hendershot LM (2003) The stressful road to antibody secretion. Nat Immunol 4(4):310-311.
22. Williamson AR, Adkonas BA (1968) Time course of labeling of light and heavy chains of immunoglobulin G and the turnover of the free light-chain intermediates. Arch Biochem Biophys 125(2):401-409.
23. Zolla S, Buxbaum J, Franklin EC, Scharff MD (1970) Synthesis and assembly of immunoglobulins by malignant human plasmacytes. I. Myelomas producing gamma-chains and light chains. J Exp Med 132(1):148-162.
24. Walter P, Ron D (2011) The unfolded protein response: From stress pathway to homeostatic regulation. Science 334(6059):1081-1086.
25. Wang S, Kaufman RJ (2012) The impact of the unfolded protein response on human disease. J Cell Biol 197(7):857-867.
26. Arendt BK, et al. (2008) Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 112(5):1931-1941.
27. Badr CE, Hewett JW, Breakefield XO, Tannous BA (2007) A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2(6):e571.
28. Hulleman JD, Balch WE, Kelly JW (2012) Translational attenuation differentially alters the fate of disease-associated fibulin proteins. FASEB J 26(11):4548-4560.
29. Hulleman JD, Brown SJ, Rosen H, Kelly JW (2013) A high-throughput cell-based Gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion. J Biomol Screen 18(6):647-658.
30. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67-73.
31. Li WW, Alexandre S, Cao X, Lee AS (1993) Transactivation of the grp78 promoter by Ca2+ depletion. A comparative analysis with A23187 and the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin. J Biol Chem 268(16):12003-12009.
32. Hägg M, et al. (2004) Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 3(4):489-497.
33. Hiramatsu N, Joseph VT, Lin JH (2011) Monitoring and manipulating mammalian unfolded protein response. Methods Enzymol 491:183-198.
34. Axten JM, et al. (2012) Discovery of 7-methyl-5-(1-[3-(trifluoromethyl)phenyl]acetyl-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 55(16):7193-7207.
35. Wang Q, Li L, Ye Y (2008) Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 283(12):7445-7454.
36. Kruse KB, Brodsky JL, McCracken AA (2006) Autophagy: An ER protein quality control process. Autophagy 2(2):135-137.
37. Ryno LM, Wiseman RL, Kelly JW (2013) Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr Opin Chem Biol 17(3):346-352.
38. Wall J, et al. (1999) Thermodynamic instability of human lambda 6 light chains: Correlation with fibrillogenicity. Biochemistry 38(42):14101-14108.
39. Klimtchuk ES, et al. (2010) The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry 49(45):9848-9857.
40. Shoulders MD, et al. (2013) Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Reports 3(4):1279-1292.
41. Chiang WC, Hiramatsu N, Messah C, Kroeger H, Lin JH (2012) Selective activation of ATF6 and PERK endoplasmic reticulum stress signaling pathways prevent mutant rhodopsin accumulation. Invest Ophthalmol Vis Sci 53(11):7159-7166.
42. Melnick J, Dul JL, Argon Y (1994) Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 370(6488):373-375.
43. Feige MJ, Hendershot LM, Buchner J (2010) How antibodies fold. Trends Biochem Sci 35(4):189-198.
44. Lachmann HJ, et al. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122(1):78-84.